International Conference on Medicinal Chemistry and Drugs Design ICMCDD on August 17-18, 2020 in City of London, United Kingdom

Track 1:Medicinal Chemistry and Drug Delivery

Medicinal chemistry-based plans are essentially aimed at the chemical modification of low molecular weight drugs in order to increase their lipophilicity or the intention of proper pro-drugs, although this assessment will concentration mainly on the use of pro-drugs and not analog development. Recently, interest has been concentrated on the design and evaluation of pro-drugs that are capable of misusing one or more of the many endogenous transport systems at the level of the blood brain barrier (BBB). The scientific plans are mostly non-invasive approaches of drug transferal to malignancies of the central nervous system (CNS) and are founded on the use of Nano systems (colloidal carriers) such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, polymeric micelles and dendrimers. The bio distribution of these Nano carriers can be manipulated by modifying their surface physico-chemical properties or by coating them with surfactants and polyethylene-glycols (PEGs). Liposomes, surfactant covered polymeric nanoparticles, and solid lipid nanoparticles are promising systems for transfer of drugs to tumors of the CNS. This mini journal discusses issues concerning the scope and limitations of both the medicinal chemistry and scientific approaches. Based on the current findings, it can be concluded that crossing of the BBB and drug transfer to CNS is very multifarious and requires a multidisciplinary approach such as a next to collaboration and collective efforts among researchers of several scientific areas, mainly medicinal chemists, biologists and pharmaceutical technicians.

Track 1-1 Target discovery and validation

Track 1-2 Molecular modeling

Track 1-3 Advances in medicinal chemistry

Track 1-4 Drug receptor interactions

Track 1-5 Toxicity, and therapeutic applications of antibiotics, antifungals, and antiviral

Track 1-6 Chemotherapeutic Agents

Track 2:Structure-based drug design, virtual screening

Structure-based drug design, virtual screening starts with processing the 3D target structural information of interest. The target structure may be derived from experimental data (X-ray, NMR or neutron scattering spectroscopy), homology modeling, or from Molecular Dynamics (MD) simulations. There are numerous fundamental issues that should be examined when considering a biological target for SBVS; for example, the drug ability of the receptor, the choice of binding site, the selection of the most relevant protein structure, incorporating receptor flexibility, suitable assignment of protonation states, and consideration of water molecules in a binding site, to name a few. In fact, the identification of ligand binding sites on biological targets is becoming increasingly important. The need for novel modulators of protein/gene function has recently directed the scientific community to pursue drug gable allosteric binding pockets. Another consideration for SBVS includes the careful choice of the compound library to be screened in the VS exercise according to the target in question, and the preprocessing of libraries in order to assign the proper stereochemistry, tautomeric, and protonation states.

Track 2-1 Protein biochemistry

Track 2-2 Organic synthesis of ligands and inhibitors

Track 2-3 Drug metabolism

Track 2-4 Molecular biology and genetic engineering

Track 2-5 Ligand and structure based drug design

Track 3:Computer Aided Drug Designing

Computer-Aided Drug Design is an important journal for all medicinal chemists who wish to be kept informed and up-to-date with all the latest and important developments in computer-aided methodologies and their applications in drug discovery. Each issue contains a series of timely, in-depth reviews mini-reviews, unique research articles and letter articles written by leaders in the field, covering a range of computational techniques for drug design, broadcast, ADME studies, theoretical chemistry; computational chemistry; computer and molecular graphics; molecular modeling; protein engineering; drug design; expert systems; general structure-property relationships; molecular dynamics; chemical database development and usage etc., providing excellent rationales for drug expansion.

Track 3-1 Computational Chemistry

Track 3-2 Enzyme as target

Track 3-3 Receptor as target

Track 3-4 QSAR/QSPR Quantitative structure activity/property relationships

Track 4:Anti-Cancer agents in Medicinal Chemistry

Cancer is one of the major health hazards and the prominent cause of death in the world. A number of anticancer agent are currently in clinical practice and used for treatment of many kinds of cancers. There is no disbelief that the current resource of anticancer agents is insufficient due to the high occurrence of side effects and multidrug resistance. In the efforts to develop appropriate anticancer drugs, medicinal chemists have focused on coumrain derivatives. Coumarin is a certainly occurring compound and a versatile synthetic scaffold owning wide spectrum of biological effects including potential anticancer activity. This journal article covers the modern improvements of coumarin-based anticancer agents and also discusses the structure activity relationship of the greatest potent compounds

Track 4-1 Classification of Anti-Cancer Drugs

Track 4-2 Chemotherapy

Track 4-3 Anticancer and Anti-Diabetic Agents

Track 4-4 Chemotherapeutic Agents

Track 5:Bioorganic & Medicinal Chemistry

Bioorganic Chemistry goes explanations of research that are at the line of chemistry and biology. The controlling principle that the Editorial Board will follow in accepting manuscripts for publication is that the study either uses the principles and skills of organic and physical organic chemistry in struggling to solve some problem of relevance to biology or describes chemical studies that are inspired by some biological observation. Within this context, manuscripts suitable for plan are ones that deal with such matters as enzymology, enzyme models, biosynthesis and combinatorial biosynthesis, biomimetic synthesis, molecular recognition, protein and peptide chemistry, nucleic acid chemistry.

Track 5-1 Bromodomain inhibitor

Track 5-2 BET proteins

Track 5-3 Apoptosis

Track 5-4 Multi-target-directed ligands

 

Name: Medicinal Chemistry 2020
Website: https://medicinalchemistry.chemistryconferences.org/
Address: london

23nd International Conference on Medicinal Chemistry & Drug Design” which is to be held during August 17-18, 2020 at London,UK which includes prompt Keynote presentations, Oral talks, Poster presentations, Workshops and Exhibitions.